Idorsia Ltd is a Swiss biopharmaceutical company specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The company was founded in 2017 as a spin-off from Actelion and is headquartered in Allschwil, Switzerland.